Collaboration for lung cancer trial

0

Bristol-Myers Squibb and Novartis announced a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of combining Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor nivolumab with three molecularly targeted oncology therapies from Novartis (ceritinib, INC280 and EGF816). Novartis will conduct two Phase 1/2 studies focused on non-small cell lung cancer (NSCLC). The studies will explore the potential of enhanced anti-tumor response using a combined immunotherapy and targeted molecular approach.

SHARE

LEAVE A REPLY

Please enter your comment!
Please enter your name here